Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Aug;85(4):552–556. doi: 10.1054/bjoc.2001.1938

Prognostic utility of human complement factor H related protein test (the BTA stat® Test)

M-P Raitanen 1,7, E Kaasinen 3, E Rintala 4, E Hansson 5, P Nieminen 6, R Aine 2, T L J Tammela 1; The Finn Bladder Group1
PMCID: PMC2364089  PMID: 11506495

Abstract

The purpose of the study was to determine, in addition to well-known prognostic factors, histological grade, stage, tumour size and multiplicity, the correlation of BTA stat Test on disease free interval (DFI) on primary superficial bladder cancer. A total of 116 patients with newly diagnosed bladder cancer were evaluated in a prospective multicentre study. A voided urine sample was obtained prior to TURB and split for culture, cytology and BTA stat testing. Follow-up data for the patients were collected until the first recurrence or the last visit and the DFI was analysed by Kaplan–Meier method and Cox analysis. Ninety-seven of the 116 (83.6%) patients were eligible for analysis. The BTA stat Test was positive in 73 (75.3%) patients, whereas cytology detected 20 (20.6%) cases. The DFI was found to be shorter among patients with a positive BTA stat Test, and also among those with intermediate or high-grade tumours. The BTA stat Test result divided patients with grade 2 tumours into two prognostic groups, in that those testing positive had 68.6% risk of recurrence during the first year compared to 42.9% risk of those with a negative test result (P = 0.041). Although the effect of tumour size on DFI was notable, the difference did not reach statistical significance (P = 0.064). Number of tumours was not related to DFI, nor was the difference between different stage of tumour of significance. BTA stat Test is not only sensitive in detection of primary bladder cancer, but also might have some independent prognostic significance. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: bladder neoplasms, tumour marker, prognosis

Full Text

The Full Text of this article is available as a PDF (66.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Fitzpatrick J. M., West A. B., Butler M. R., Lane V., O'Flynn J. D. Superficial bladder tumors (stage pTa, grades 1 and 2): the importance of recurrence pattern following initial resection. J Urol. 1986 May;135(5):920–922. doi: 10.1016/s0022-5347(17)45923-4. [DOI] [PubMed] [Google Scholar]
  2. Heney N. M., Ahmed S., Flanagan M. J., Frable W., Corder M. P., Hafermann M. D., Hawkins I. R. Superficial bladder cancer: progression and recurrence. J Urol. 1983 Dec;130(6):1083–1086. doi: 10.1016/s0022-5347(17)51695-x. [DOI] [PubMed] [Google Scholar]
  3. Heney N. M., Nocks B. N., Daly J. J., Prout G. R., Jr, Newall J. B., Griffin P. P., Perrone T. L., Szyfelbein W. A. Ta and T1 bladder cancer: location, recurrence and progression. Br J Urol. 1982 Apr;54(2):152–157. doi: 10.1111/j.1464-410x.1982.tb13538.x. [DOI] [PubMed] [Google Scholar]
  4. Kiemeney L. A., Witjes J. A., Heijbroek R. P., Verbeek A. L., Debruyne F. M. Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer. J Urol. 1993 Jul;150(1):60–64. doi: 10.1016/s0022-5347(17)35397-1. [DOI] [PubMed] [Google Scholar]
  5. Kinders R., Jones T., Root R., Bruce C., Murchison H., Corey M., Williams L., Enfield D., Hass G. M. Complement factor H or a related protein is a marker for transitional cell cancer of the bladder. Clin Cancer Res. 1998 Oct;4(10):2511–2520. [PubMed] [Google Scholar]
  6. Koch M., Hill G. B., McPhee M. S. Factors affecting recurrence rates in superficial bladder cancer. J Natl Cancer Inst. 1986 Jun;76(6):1025–1029. [PubMed] [Google Scholar]
  7. Kurth K. H., Denis L., Bouffioux C., Sylvester R., Debruyne F. M., Pavone-Macaluso M., Oosterlinck W. Factors affecting recurrence and progression in superficial bladder tumours. Eur J Cancer. 1995 Oct;31A(11):1840–1846. doi: 10.1016/0959-8049(95)00287-s. [DOI] [PubMed] [Google Scholar]
  8. Lutzeyer W., Rübben H., Dahm H. Prognostic parameters in superficial bladder cancer: an analysis of 315 cases. J Urol. 1982 Feb;127(2):250–252. doi: 10.1016/s0022-5347(17)53725-8. [DOI] [PubMed] [Google Scholar]
  9. Malmström P. U., Busch C., Norlén B. J. Recurrence, progression and survival in bladder cancer. A retrospective analysis of 232 patients with greater than or equal to 5-year follow-up. Scand J Urol Nephrol. 1987;21(3):185–195. doi: 10.3109/00365598709180320. [DOI] [PubMed] [Google Scholar]
  10. Morris S. B., Gordon E. M., Shearer R. J., Woodhouse C. R. Superficial bladder cancer: for how long should a tumour-free patient have check cystoscopies? Br J Urol. 1995 Feb;75(2):193–196. doi: 10.1111/j.1464-410x.1995.tb07310.x. [DOI] [PubMed] [Google Scholar]
  11. Parmar M. K., Freedman L. S., Hargreave T. B., Tolley D. A. Prognostic factors for recurrence and followup policies in the treatment of superficial bladder cancer: report from the British Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). J Urol. 1989 Aug;142(2 Pt 1):284–288. doi: 10.1016/s0022-5347(17)38731-1. [DOI] [PubMed] [Google Scholar]
  12. Pode D., Shapiro A., Wald M., Nativ O., Laufer M., Kaver I. Noninvasive detection of bladder cancer with the BTA stat test. J Urol. 1999 Feb;161(2):443–446. [PubMed] [Google Scholar]
  13. Raitanen M. P., Marttila T., Kaasinen E., Rintala E., Aine R., Tammela T. L. Sensitivity of human complement factor H related protein (BTA stat) test and voided urine cytology in the diagnosis of bladder cancer. J Urol. 2000 Jun;163(6):1689–1692. [PubMed] [Google Scholar]
  14. Raitanen M. P., Tammela T. L. Impact of tumour grade, stage, number and size, smoking habits and sex on the recurrence rate and disease-free interval in patients with transitional cell carcinoma of the bladder. Ann Chir Gynaecol. 1995;84(1):37–41. [PubMed] [Google Scholar]
  15. Sarosdy M. F., Hudson M. A., Ellis W. J., Soloway M. S., deVere White R., Sheinfeld J., Jarowenko M. V., Schellhammer P. F., Schervish E. W., Patel J. V. Improved detection of recurrent bladder cancer using the Bard BTA stat Test. Urology. 1997 Sep;50(3):349–353. doi: 10.1016/s0090-4295(97)00292-6. [DOI] [PubMed] [Google Scholar]
  16. Thompson R. A., Jr, Campbell E. W., Jr, Kramer H. C., Jacobs S. C., Naslund M. J. Late invasive recurrence despite long-term surveillance for superficial bladder cancer. J Urol. 1993 May;149(5):1010–1011. doi: 10.1016/s0022-5347(17)36282-1. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES